Trial Profile
A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms CheckMate140
- Sponsors Bristol-Myers Squibb
- 13 Dec 2021 Status changed from active, no longer recruiting to completed.
- 29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 21 Jan 2021 Planned number of patients changed from 90 to 115.